The EU Commission clears, subject to divestiture, a merger in the pharmaceutical industry (Hoffmann-La Roche / Boehringer Mannheim)

Emberger, Geraldine; Kemp, John

Previous article The EU Commission approves a merger between two Swiss based companies active in private and corporate banking and in the financial services business (Schweizerische Bankgesellschaft / Schweizerische Bankverein) Next article The EU Commission launches an initiative for the reorientation of State aid control procedures

4 Feb 1998

The EU Commission clears, subject to divestiture, a merger in the pharmaceutical industry (Hoffmann-La Roche / Boehringer Mannheim)

KEYWORDS

Reference

EU Commission, Hoffmann-La Roche / Boehringer Mannheim, Case COMP/M.950, 4 February 1998

"Mergers Recent important decisions" In September 1997, the Swiss pharmaceutical company Hoffmann-La Roche proposed to acquire Corage Ltd., ultimate parent company of the Boehringer Mannheim Group (BM). After a preliminary appreciation of the case the Commission concluded that in clinical chemistry (‘CC’) in

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Geraldine Emberger
European Commission - DG TRADE (Brussels)

Belgium 25 contributions 5682 visits
John Kemp
DG COMP (Brussels)

Belgium 22 contributions 5147 visits

Quotation

Geraldine Emberger, John Kemp, The EU Commission clears, subject to divestiture, a merger in the pharmaceutical industry (Hoffmann-La Roche / Boehringer Mannheim), 4 February 1998, e-Competitions February 1998, Art. N° 39443

Visites 295